THE BIOMARKERS MARKET SIZE WAS VALUED AT USD 45.11 BILLION IN 2021 AND IS EXPECTED TO REACH USD 86.41 BILLION BY 2027, GROWING AT A CAGR OF 11.44% DURING THE FORECAST PERIOD.

Biomarkers Market Share, Size Trends Analysis, by-

  • Indication: Oncology, Cardiology, Neurology, Immunology, and Others
  • Application: Diagnostics, Drug Discovery & Development, Personalized Medicine (PM), and Others
  • Type: Diagnostic Biomarker, Monitoring Biomarker, Prognostic Biomarker, Susceptibility Biomarker, and Other Biomarker
  • Geography: North America, Europe, APAC, Latin America, and Middle East & Africa

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022-2027

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

302 Pages

icon-table

65 Tables

icon-chart

159 Charts

icon-region

5 Regions

icon-country

18 Countries

icon-company

31 Companies

icon-market

4 Market Segment

BIOMARKERS MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (2027) USD 86.41 BILLION
MARKET SIZE (2021) USD 45.11 BILLION
CAGR (2022-2027) 11.41%
FASTEST GROWING REGION Asia-Pacific
MARKET SEGMENTS Indication (Oncology, Cardiology, Neurology, Immunology and Others), Application (Diagnostics, Drug Discovery & Development, Personalized Medicine (PM), and Others), Type (Diagnostic Biomarker, Monitoring Biomarker, Prognostic Biomarker, Susceptibility Biomarker, and Other Biomarker)
REGION WITH HIGHEST SHARE NORTH AMERICA
GEOGRAPHIC ANALYSIS North America, Europe, APAC, Latin America, and Middle East & Africa
COUNTRIES COVERED US, Canada, Germany, France, UK, Italy, Spain, Japan, China, India, South Korea, Australia, Brazil, Mexico, Argentina, Turkey, South Africa, Saudi Arabia

BIOMARKERS MARKET OVERVIEW

The biomarkers market size was valued at USD 45.11 billion in 2021 and is expected to reach USD 86.41 billion by 2027, growing at a CAGR of 11.44% during the forecast period.

Increasing adoption of biomarkers in personalized medicine and a growing focus on digital biomarkers fuel market growth. Biomarkers are increasingly valuable tools for predicting prognosis and therapy response in cancer patients. Furthermore, it allows for improving understanding of mechanisms of action and resistance to treatment. It is a rapidly advancing area in autoimmune disease. Various researchers have been working on discovering new biomarkers, including autoantibodies in autoimmune diseases.

Vendors are focusing on increasing biomarker discoveries and biomarker-based diagnostics development because of the high demand in diagnostics for personalized medicine and drug discovery and development. The vendor’s focus is on fitting treatments to patients; providing the right therapy for the right group of people at the right time is increasing the demand for biomarkers research.

Biomarkers Market Size

KEY HIGHLIGHTS

  • Increased Adoption of Biomarkers in Personalized Medicine is driving the global biomarkers market growth. As many healthcare settings have gained interest in personalized/precision medicine, many vendors have increased the studies focussing on identifying biomarkers to provide healthcare system solutions to them.
  • Increasing focus on digital biomarkers will also drive the global  Currently, several digital biomarkers are being tested for feasibility and reliability in Parkinson’s and Alzheimer's disease and clinical outcome assessments.
  • Increasing discovery of epigenetic biomarkers for oncology is also driving the biomarker technologies market. More emerging companies are increasing their research & development focus on discovering more epigenetics to diagnose various types of cancers.
  • Technological Advancements in genomic biomarker discovery also positively impact the biomarkers diagnostics industry. For instance, a recent development in portable biosensors allows rapid, accurate, and on-site detection of biomarkers, which helps prevent disease spread by controlling sources.

BIOMARKERS MARKET SEGMENTATION

  • In 2021, the oncology segment accounted for more than 30% of the global market share. Biomarkers are highly in use in cancer research and medicine. Now, physicians are increasingly using cancer biomarkers to gain more information about a patient's tumor to predict the treatment that is most likely to work against their unique cancer.
  • By application, the diagnostics segment will lead in the biomarkers industry. Biomarkers are critical to the rational development of medical diagnostics and therapeutics. Complex composite and digital biomarkers derived from sensors and mobile technologies and biomarker-driven predictive toxicology and systems pharmacology are reshaping the development of diagnostic and therapeutic technologies in the genomic biomarkers market.
  • The diagnostic biomarkers market segment will witness the highest growth. Many diseases have subtypes with markedly different prognoses or responses to a specific treatment. Diagnostic biomarkers that identify disease subtypes thus often play critical roles when the results of diagnostic classification are used as prognostic biomarkers and predictive biomarkers.

GEOGRAPHICAL ANALYSIS

  • North America: North America accounted for the highest share of the biomarkers market. Personalized medicine is rapidly increasing attention in North America with the increasing number of projects and funds. In recent years, the FDA has expanded its approval in new gene therapy for treating a rare disease; and has also qualified the first digital technology platform via its pre-certification program. There are also opportunities coming up in the future to adopt more advanced technologies in the US, such as digital biomarkers, to make disease management more effortless.
  • APAC: APAC region had the highest growth rate among all regions in the biomarkers industry. High-income countries such as China, Japan, and Australia have been the top sharers of biomarkers in the APAC region. The biomarker market in India and South Korea is driven by rising medical costs of treatments, chronic illness, and an aging population. The south Korean precision medicine market is predicted to grow strongly over ten years. In recent years, South Korea has started making huge investments in the development of personalized medicine, using big data to foster start-up companies in the biotech industry in the upcoming years.

VENDOR LANDSCAPE

  • The major players in the market are Abbott company, BioMerieux, Biohit OYJ, CENTOGENE, Creative Diagnostics, Hoffmann-La Roche company, Fujirebio, and General Electric (GE) company, and TAmiRNA.
  • Vendors also need to develop new product launches providing enough clinical trial data to get easy approval from regulatory bodies.
  • Multiple companies partnering and investing in biomarkers research and development will help the companies to innovate new drugs and reduce the economic burden.
  • Vendors need to strategically focus on inorganic growth through mergers and acquisitions, increasing the collaborations with various research organizations academic, and also bringing out initiatives socio-economically to raise the awareness

The biomarkers market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

Segmentation by Indication

  • Oncology
  • Cardiology
  • Neurology
  • Immunology
  • Others

Segmentation by Application

  • Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine (PM)
  • Others

Segmentation by Type

  • Diagnostic Biomarker
  • Monitoring Biomarker
  • Prognostic Biomarker
  • Susceptibility Biomarker
  • Other Biomarker

Segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • South Africa
    • Saudi Arabia

Frequently Asked Questions

What is the current size of the global biomarkers market?

The biomarkers market size was valued at USD 45.11 billion in 2021 and is expected to reach USD 86.41 billion by 2027, growing at a CAGR of 11.44% during the forecast period.

Who are the leading players in the biomarkers market?

The major players in the biomarkers market are Abbott company, BioMerieux, Biohit OYJ, CENTOGENE, Creative Diagnostics, F. Hoffmann-La Roche company, Fujirebio, General Electric (GE) company, and TAmiRNA.

What are the major drivers of the biomarkers market?

Increasing adoption in precision medicine, the growing popularity of digital biomarkers, the number of pipeline biomarkers, and rising adoption in disease diagnostics are significant drivers.

Which region has the highest share in the industry?

North America has the highest share in the biomarkers industry.

Which application segment is leading in the biomarkers industry?

In terms of application, the diagnostics segment will lead the industry.

Download Free Sample

The biomarkers market was valued at USD 45.11 billion in 2021 and is expected to reach USD 86.41 billion by 2027, growing at a CAGR of 11.44% during the forecast period 

The following factors are likely to contribute to the growth of the biomarkers market-

  • Increased Adoption of Biomarkers in Personalized Medicine
  • Increasing Focus on Digital Biomarkers
  • Increasing Discovery of Epigenetic Biomarkers for Oncology
  • Increase in Number of Pipeline Biomarkers
  • Rising Adoption of Biomarkers in Disease Diagnostics

Base Year: 2021

Forecast Year: 2022-2027

The study considers a detailed scenario of the present biomarkers market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

KEY VENDORS

  • Abbott company
  • BioMerieux
  • Biohit OYJ
  • CENTOGENE
  • Creative Diagnostics
  • F. Hoffmann-La Roche company
  • Fujirebio
  • General Electric (GE) company
  • TAmiRNA

Other Prominent Vendors

  • Accure Therapeutics
  • Agilent
  • Almac Group
  • Applied Research Using OMIC Sciences (AROMICS)
  • Bio-Rad Laboratories
  • BioVision
  • Caris Life Sciences
  • Denovo Biopharma
  • Dreamgenics
  • Eisai
  • Epigenomics
  • Immunovia
  • Insilico Medicine
  • Lexogen
  • Monument Tx
  • Oryzon Genomics
  • Plexision
  • Rules-Based Medicine
  • Siemens Healthineers
  • Second Genome Therapeutics
  • Thermo Fisher Scientific
  • Ymir Genomics

Segmentation by Indication

  • Oncology
  • Cardiology
  • Neurology
  • Immunology
  • Others

Segmentation by Application

  • Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine (PM)
  • Others

Segmentation by Type

  • Diagnostic Biomarker
  • Monitoring Biomarker
  • Prognostic Biomarker
  • Susceptibility Biomarker
  • Other Biomarker

Segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • South Africa
    • Saudi Arabia

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 MARKET DEFINITION

4.1.1 INCLUSIONS

4.1.2 EXCLUSIONS

4.1.3 MARKET ESTIMATION CAVEATS

4.2 BASE YEAR

4.3 SCOPE OF THE STUDY

4.4 MARKET SEGMENTS

4.4.1 MARKET SEGMENTATION BY INDICATION

4.4.2 MARKET SEGMENTATION BY APPLICATION

4.4.3 MARKET SEGMENTATION BY TYPE

4.4.5 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

5.1 KEY CAVEATS

5.2 CURRENCY CONVERSION

5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION

7.1 OVERVIEW

8 MARKET OPPORTUNITIES & TRENDS

8.1 INCREASED ADOPTION OF BIOMARKERS IN PERSONALIZED MEDICINE

8.2 INCREASING FOCUS ON DIGITAL BIOMARKERS

8.3 INCREASED DISCOVERY OF EPIGENETIC BIOMARKERS IN ONCOLOGY

9 MARKET GROWTH ENABLERS

9.1 INCREASE IN THE NUMBER OF PIPELINE BIOMARKERS

9.2 RISING ADOPTION OF BIOMARKERS IN DISEASE DIAGNOSTICS

9.3 TECHNOLOGICAL ADVANCEMENTS IN BIOMARKER DISCOVERY

10 MARKET RESTRAINTS

10.1 HIGH COST AND TIME-CONSUMING DEVELOPMENT

10.2 HIGH NUMBER OF FALSE DISCOVERIES

10.3 STRICT REGULATIONS AND ETHICS FOR BIOMARKER VALIDATION & QUALIFICATION

11 MARKET LANDSCAPE

11.1 MARKET OVERVIEW

11.2 MARKET SIZE & FORECAST

11.2.1 INSIGHTS BY INDICATION

11.2.2 INSIGHTS BY APPLICATION

11.2.3 INSIGHTS BY TYPE

11.2.4 INSIGHTS BY GEOGRAPHY

11.3 FIVE FORCES ANALYSIS

11.3.1 THREAT OF NEW ENTRANTS

11.3.2 BARGAINING POWER OF SUPPLIERS

11.3.3 BARGAINING POWER OF BUYERS

11.3.4 THREAT OF SUBSTITUTES

11.3.5 COMPETITIVE RIVALRY

12 INDICATION

12.1 MARKET SNAPSHOT & GROWTH ENGINE

12.2 MARKET OVERVIEW

12.3 ONCOLOGY

12.3.1 MARKET OVERVIEW

12.3.2 MARKET SIZE & FORECAST

12.3.3 MARKET BY GEOGRAPHY

12.4 CARDIOLOGY

12.4.1 MARKET OVERVIEW

12.4.2 MARKET SIZE & FORECAST

12.4.3 MARKET BY GEOGRAPHY

12.5 NEUROLOGY

12.5.1 MARKET OVERVIEW

12.5.2 MARKET SIZE & FORECAST

12.5.3 MARKET BY GEOGRAPHY

12.6 IMMUNOLOGY

12.6.1 MARKET OVERVIEW

12.6.2 MARKET SIZE & FORECAST

12.6.3 MARKET BY GEOGRAPHY

12.7 OTHERS

12.7.1 MARKET OVERVIEW

12.7.2 MARKET SIZE & FORECAST

12.7.3 MARKET BY GEOGRAPHY

13 APPLICATION

13.1 MARKET SNAPSHOT & GROWTH ENGINE

13.2 MARKET OVERVIEW

13.3 DIAGNOSTICS

13.3.1 MARKET OVERVIEW

13.3.2 MARKET SIZE & FORECAST

13.3.3 MARKET BY GEOGRAPHY

13.4 DRUG DISCOVERY & DEVELOPMENT

13.4.1 MARKET OVERVIEW

13.4.2 MARKET SIZE & FORECAST

13.4.3 MARKET BY GEOGRAPHY

13.5 PERSONALIZED MEDICINE

13.5.1 MARKET OVERVIEW

13.5.2 MARKET SIZE & FORECAST

13.5.3 MARKET BY GEOGRAPHY

13.6 OTHERS

13.6.1 MARKET OVERVIEW

13.6.2 MARKET SIZE & FORECAST

13.6.3 MARKET BY GEOGRAPHY

14 TYPE

14.1 MARKET SNAPSHOT & GROWTH ENGINE

14.2 MARKET OVERVIEW

14.3 DIAGNOSTIC BIOMARKERS

14.3.1 MARKET OVERVIEW

14.3.2 MARKET SIZE & FORECAST

14.3.3 MARKET BY GEOGRAPHY

14.4 MONITORING BIOMARKERS

14.4.1 MARKET OVERVIEW

14.4.2 MARKET SIZE & FORECAST

14.4.3 MARKET BY GEOGRAPHY

14.5 PROGNOSTIC BIOMARKERS

14.5.1 MARKET OVERVIEW

14.5.2 MARKET SIZE & FORECAST

14.5.3 MARKET BY GEOGRAPHY

14.6 PREDICTIVE BIOMARKERS

14.6.1 MARKET OVERVIEW

14.6.2 MARKET SIZE & FORECAST

14.6.3 MARKET BY GEOGRAPHY

14.7 SUSCEPTIBILITY BIOMARKERS

14.7.1 MARKET OVERVIEW

14.7.2 MARKET SIZE & FORECAST

14.7.3 MARKET BY GEOGRAPHY

14.8 OTHER BIOMARKERS

14.8.1 MARKET OVERVIEW

14.8.2 MARKET SIZE & FORECAST

14.8.3 MARKET BY GEOGRAPHY

15 GEOGRAPHY

15.1 MARKET SNAPSHOT & GROWTH ENGINE

15.2 GEOGRAPHIC OVERVIEW

16 NORTH AMERICA

16.1 MARKET OVERVIEW

16.2 MARKET SIZE & FORECAST

16.3 NORTH AMERICA: TYPE

16.4 NORTH AMERICA: APPLICATION

16.5 NORTH AMERICA: INDICATION

16.6 KEY COUNTRIES

16.6.1 US: MARKET SIZE & FORECAST

16.6.2 CANADA: MARKET SIZE & FORECAST

17 EUROPE

17.1 MARKET OVERVIEW

17.2 MARKET SIZE & FORECAST

17.3 EUROPE: TYPE

17.4 EUROPE: APPLICATION

17.5 EUROPE: INDICATION

17.6 KEY COUNTRIES

17.6.1 GERMANY: MARKET SIZE & FORECAST

17.6.2 FRANCE: MARKET SIZE & FORECAST

17.6.3 UK: MARKET SIZE & FORECAST

17.6.4 ITALY: MARKET SIZE & FORECAST

17.6.5 SPAIN: MARKET SIZE & FORECAST

18 APAC

18.1 MARKET OVERVIEW

18.2 APAC: TYPE

18.3 APAC: APPLICATION

18.4 APAC: INDICATION

18.5 KEY COUNTRIES

18.5.1 JAPAN: MARKET SIZE & FORECAST

18.5.2 CHINA: MARKET SIZE & FORECAST

18.5.3 INDIA: MARKET SIZE & FORECAST

18.5.4 SOUTH KOREA: MARKET SIZE & FORECAST

18.5.5 AUSTRALIA: MARKET SIZE & FORECAST

19 LATIN AMERICA

19.1 MARKET OVERVIEW

19.2 LATIN AMERICA: TYPE

19.3 LATIN AMERICA: APPLICATION

19.4 LATIN AMERICA: INDICATION

19.5 KEY COUNTRIES

19.5.1 BRAZIL: MARKET SIZE & FORECAST

19.5.2 MEXICO: MARKET SIZE & FORECAST

19.5.3 ARGENTINA: MARKET SIZE & FORECAST

20 MIDDLE EAST & AFRICA

20.1 MARKET OVERVIEW

20.2 MARKET SIZE & FORRECAST

20.3 MIDDLE EAST & AFRICA: TYPE

20.4 MIDDLE EAST & AFRICA: APPLICATION

20.5 MIDDLE EAST & AFRICA: INDICATION

20.6 KEY COUNTRIES

20.6.1 TURKEY: MARKET SIZE & FORECAST

20.6.2 SOUTH AFRICA: MARKET SIZE & FORECAST

20.6.3 SAUDI ARABIA: MARKET SIZE & FORECAST

21 COMPETITIVE LANDSCAPE

21.1 COMPETITION OVERVIEW

21.2 MARKET SHARE ANALYSIS

21.2.1 ABBOTT

21.2.2 BIOMÉRIEUX

21.2.3 BIOHIT OYJ

21.2.4 CENTOGENE

21.2.5 CREATIVE DIAGNOSTICS

21.2.6 GE HEALTHCARE

21.2.7 ROCHE

21.2.8 TAMIRNA

21.2.9 FUJIREBIO

22 KEY COMPANY PROFILES

22.1 ABBOTT

22.1.1 BUSINESS OVERVIEW

22.1.2 MAJOR PRODUCT OFFERINGS

22.1.3 KEY STRATEGIES

22.1.4 KEY STRENGTHS

22.1.5 KEY OPPORTUNITIES

22.2 BIOMÉRIEUX

22.2.1 BUSINESS OVERVIEW

22.2.2 MAJOR PRODUCT OFFERINGS

22.2.3 KEY STRATEGIES

22.2.4 KEY STRENGTHS

22.2.5 KEY OPPORTUNITIES

22.3 BIOHIT OYJ

22.3.1 BUSINESS OVERVIEW

22.3.2 MAJOR PRODUCT OFFERINGS

22.3.3 KEY STRATEGIES

22.3.4 KEY STRENGTHS

22.3.5 KEY OPPORTUNITIES

22.4 CENTOGENE

22.4.1 BUSINESS OVERVIEW

22.4.2 MAJOR PRODUCT OFFERINGS

22.4.3 KEY STRATEGIES

22.4.4 KEY STRENGTHS

22.4.5 KEY OPPORTUNITIES

22.5 CREATIVE DIAGNOSTICS

22.5.1 BUSINESS OVERVIEW

22.5.2 MAJOR PRODUCT OFFERINGS

22.5.3 KEY STRATEGIES

22.5.4 KEY STRENGTHS

22.5.5 KEY OPPORTUNITIES

22.6 F. HOFFMANN-LA ROCHE

22.6.1 BUSINESS OVERVIEW

22.6.2 MAJOR PRODUCT OFFERINGS

22.6.3 KEY STRATEGIES

22.6.4 KEY STRENGTHS

22.6.5 KEY OPPORTUNITIES

22.7 FUJIREBIO

22.7.1 BUSINESS OVERVIEW

22.7.2 MAJOR PRODUCT OFFERINGS

22.7.3 KEY STRATEGIES

22.7.4 KEY STRENGTHS

22.7.5 KEY OPPORTUNITIES

22.8 GE HEALTHCARE

22.8.1 BUSINESS OVERVIEW

22.8.2 PRODUCT OFFERINGS

22.8.3 KEY STRATEGIES

22.8.4 KEY STRENGTHS

22.8.5 KEY OPPORTUNITIES

22.9 TAMIRNA

22.9.1 BUSINESS OVERVIEW

22.9.2 MAJOR PRODUCT OFFERINGS

22.9.3 KEY STRATEGIES

22.9.4 KEY STRENGTHS

22.9.5 KEY OPPORTUNITIES

23 OTHER PROMINENT VENDORS

23.1 ACCURE THERAPEUTICS

23.1.1 BUSINESS OVERVIEW

23.2 AGILENT

23.2.1 BUSINESS OVERVIEW

23.3 ALMAC GROUP

23.3.1 BUSINESS OVERVIEW

23.4 APPLIED RESEARCH USING OMIC SCIENCES (AROMICS)

23.4.1 BUSINESS OVERVIEW

23.5 BIO-RAD LABORATORIES

23.5.1 BUSINESS OVERVIEW

23.6 BIOVISION

23.6.1 BUSINESS OVERVIEW

23.7 CARIS LIFE SCIENCES

23.7.1 BUSINESS OVERVIEW

23.8 DENOVO BIOPHARMA

23.8.1 BUSINESS OVERVIEW

23.9 DREAMGENICS

23.9.1 BUSINESS OVERVIEW

23.10 EISAI

23.10.1 BUSINESS OVERVIEW

23.11 EPIGENOMICS

23.11.1 BUSINESS OVERVIEW

23.12 IMMUNOVIA

23.12.1 BUSINESS OVERVIEW

23.13 INSILICO MEDICINE

23.13.1 BUSINESS OVERVIEW

23.14 LEXOGEN

23.14.1 BUSINESS OVERVIEW

23.15 MONUMENT TX

23.15.1 BUSINESS OVERVIEW

23.16 ORYZON GENOMICS

23.16.1 BUSINESS OVERVIEW

23.17 PLEXISION

23.17.1 BUSINESS OVERVIEW

23.18 RULES-BASED MEDICINE

23.18.1 BUSINESS OVERVIEW

23.19 SIEMENS HEALTHINEERS

23.19.1 BUSINESS OVERVIEW

23.20 SECOND GENOME THERAPEUTICS

23.20.1 BUSINESS OVERVIEW

23.21 THERMO FISHER SCIENTIFIC

23.21.1 BUSINESS OVERVIEW

23.22 YMIR GENOMICS

23.22.1 BUSINESS OVERVIEW

24 REPORT SUMMARY

24.1 KEY TAKEAWAYS

24.2 STRATEGIC RECOMMENDATIONS

25 QUANTITATIVE SUMMARY

25.1 MARKET BY GEOGRAPHY

25.2 MARKET BY INDICATION

25.3 MARKET BY APPLICATION

25.4 MARKET BY TYPE

25.5 NORTH AMERICA MARKET BY INDICATION

25.6 NORTH AMERICA MARKET BY APPLICATION

25.7 NORTH AMERICA MARKET BY TYPE

25.8 EUROPE MARKET BY INDICATION

25.9 EUROPE MARKET BY APPLICATION

25.10 EUROPE MARKET BY TYPE

25.11 APAC MARKET BY INDICATION

25.12 APAC MARKET BY APPLICATION

25.13 APAC MARKET BY TYPE

25.14 LATIN AMERICA MARKET BY INDICATION

25.15 LATIN AMERICA MARKET BY APPLICATION

25.16 LATIN AMERICA MARKET BY TYPE

25.17 MIDDLE EAST & AFRICA MARKET BY INDICATION

25.18 MIDDLE EAST & AFRICA MARKET BY APPLICATION

25.19 MIDDLE EAST & AFRICA MARKET BY TYPE

26 APPENDIX

26.1 ABBREVIATIONS

LIST OF EXHIBITS

EXHIBIT 1 SEGMENTATION OF GLOBAL BIOMARKERS MARKET

EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021

EXHIBIT 3 OVERVIEW OF BIOMARKER DEVELOPMENT PROCESS

EXHIBIT 4 VARIOUS ORGANIZATIONAL STRUCTURES PREVALENT AMONG BIOMARKER DISCOVERY ORGANIZATIONS (PERCENT OF TOP-20 PHARMACEUTICAL COMPANIES)

EXHIBIT 5 IMPACT OF INCREASED ADOPTION OF BIOMARKERS IN PERSONALIZED MEDICINE

EXHIBIT 6 NUMBER OF APPROVALS OF BIOMARKER-DRIVEN PERSONALIZED MEDICINE 2008-2018

EXHIBIT 7 COMPANION DIAGNOSTICS PIPELINE IN PERSONALIZED MEDICINE

EXHIBIT 8 IMPACT OF INCREASING FOCUS ON DIGITAL BIOMARKERS

EXHIBIT 9 IMPACT OF INCREASING DISCOVERY OF EPIGENETIC BIOMARKERS IN ONCOLOGY

EXHIBIT 10 IMPACT OF INCREASE IN THE NUMBER OF PIPELINE BIOMARKERS

EXHIBIT 11 IMPACT OF RISING ADOPTION OF BIOMARKERS IN DISEASE DIAGNOSTICS

EXHIBIT 12 IMPACT OF TECHNOLOGICAL ADVANCEMENTS IN BIOMARKER DISCOVERY

EXHIBIT 13 IMPACT OF HIGH COST AND TIME-CONSUMING DEVELOPMENT

EXHIBIT 14 BIOMARKER IDENTIFICATION, DEVELOPMENT, AND VALIDATION LIFECYCLE

EXHIBIT 15 GENERAL COST RANGE BY BIOMARKER CATEGORY

EXHIBIT 16 IMPACT OF HIGH NUMBER OF FALSE DISCOVERIES

EXHIBIT 17 IMPACT OF STRICT REGULATIONS AND ETHICS FOR BIOMARKER VALIDATION & QUALIFICATION

EXHIBIT 18 GLOBAL BIOMARKERS MARKET 2021–2027 ($ BILLION)

EXHIBIT 19 GLOBAL BIOMARKERS MARKET SHARE BY INDICATION 2021 & 2027 (%)

EXHIBIT 20 GLOBAL BIOMARKERS MARKET SHARE BY APPLICATION 2021 & 2027 (%)

EXHIBIT 21 GLOBAL BIOMARKERS MARKET SHARE BY TYPE 2021 & 2027 (%)

EXHIBIT 22 GLOBAL BIOMARKERS MARKET SHARE BY GEOGRAPHY 2021 & 2027 (%)

EXHIBIT 23 FIVE FORCES ANALYSIS 2021

EXHIBIT 24 INCREMENTAL GROWTH BY INDICATION 2021 & 2027

EXHIBIT 25 GLOBAL BIOMARKERS MARKET BY INDICATION

EXHIBIT 26 GLOBAL BIOMARKERS MARKET BY INDICATION – INCREMENTAL GROWTH ($ BILLION)

EXHIBIT 27 GLOBAL BIOMARKERS ONCOLOGY MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 28 GLOBAL BIOMARKERS ONCOLOGY MARKET 2021–2027 ($ BILLION)

EXHIBIT 29 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 30 GLOBAL BIOMARKERS CARDIOLOGY MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 31 GLOBAL BIOMARKERS CARDIOLOGY MARKET 2021–2027 ($ BILLION)

EXHIBIT 32 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 33 GLOBAL BIOMARKERS NEUROLOGY MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 34 GLOBAL BIOMARKERS NEUROLOGY MARKET 2021–2027 ($ BILLION)

EXHIBIT 35 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 36 GLOBAL BIOMARKERS IMMUNOLOGY MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 37 GLOBAL BIOMARKERS IMMUNOLOGY MARKET 2021–2027 ($ BILLION)

EXHIBIT 38 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 39 GLOBAL BIOMARKERS OTHER INDICATIONS MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 40 GLOBAL BIOMARKERS OTHER INDICATIONS MARKET 2021–2027 ($ BILLION)

EXHIBIT 41 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 42 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027

EXHIBIT 43 GLOBAL BIOMARKERS MARKET BY APPLICATION

EXHIBIT 44 GLOBAL BIOMARKERS MARKET BY APPLICATION – INCREMENTAL GROWTH ($ BILLION)

EXHIBIT 45 GLOBAL BIOMARKERS MARKET BY APPLICATION – ABSOLUTE GROWTH (%)

EXHIBIT 46 TYPES OF BIOMARKERS LIKELY TESTED FOR DIAGNOSIS OF CANCER IN THE US BY 2018

EXHIBIT 47 GLOBAL BIOMARKERS DIAGNOSTICS MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 48 GLOBAL BIOMARKERS DIAGNOSTICS MARKET 2021–2027 ($ BILLION)

EXHIBIT 49 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 50 GLOBAL BIOMARKERS DRUG DISCOVERY & DEVELOPMENT MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 51 DRUG DISCOVERY & DEVELOPMENT PROCESSES WITH THE POTENTIAL TO BENEFIT FROM BIOMARKERS PHASE I, II, AND III

EXHIBIT 52 GLOBAL BIOMARKERS DRUG DISCOVERY & DEVELOPMENT MARKET 2021–2027 ($ BILLION)

EXHIBIT 53 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 54 APPLICATION AREAS OF PM

EXHIBIT 55 GLOBAL BIOMARKERS PERSONALIZED MEDICINE MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 56 GLOBAL BIOMARKERS PERSONALIZED MEDICINE MARKET 2021–2027 ($ BILLION)

EXHIBIT 57 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 58 GLOBAL BIOMARKERS OTHER APPLICATIONS MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 59 GLOBAL BIOMARKERS OTHER APPLICATIONS MARKET 2021–2027 ($ BILLION)

EXHIBIT 60 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 61 INCREMENTAL GROWTH BY TYPE 2021 & 2027

EXHIBIT 62 GLOBAL BIOMARKERS MARKET BY TYPE

EXHIBIT 63 GLOBAL BIOMARKERS MARKET BY TYPE – INCREMENTAL GROWTH ($ BILLION)

EXHIBIT 64 GLOBAL BIOMARKERS MARKET BY TYPE – ABSOLUTE GROWTH (%)

EXHIBIT 65 GLOBAL DIAGNOSTIC BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 66 CHROMATIN CONFORMATION: PROGNOSTIC AND PREDICTIVE BIOMARKERS WITH DIAGNOSTIC UTILITY

EXHIBIT 67 GLOBAL DIAGNOSTIC BIOMARKERS MARKET 2021–2027 ($ BILLION)

EXHIBIT 68 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 69 GLOBAL MONITORING BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 70 GLOBAL MONITORING BIOMARKERS MARKET 2021–2027 ($ BILLION)

EXHIBIT 71 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 72 GLOBAL PROGNOSTIC BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 73 GLOBAL PROGNOSTIC BIOMARKERS MARKET 2021–2027 ($ BILLION)

EXHIBIT 74 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 75 GLOBAL PREDICTIVE BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 76 GLOBAL PREDICTIVE BIOMARKERS MARKET 2021–2027 ($ BILLION)

EXHIBIT 77 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 78 GLOBAL SUSCEPTIBILITY BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 79 GLOBAL SUSCEPTIBILITY BIOMARKERS MARKET 2021–2027 ($ BILLION)

EXHIBIT 80 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 81 SELECTED PHARMACODYNAMICS MARKERS IN TUMOR AND SURROGATE TISSUES

EXHIBIT 82 GLOBAL OTHER BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 83 CURRENT EMERGING SAFETY BIOMARKERS OPPORTUNITIES FOR QUALIFICATION

EXHIBIT 84 PERCENTAGE OF COMPANIES USING EMERGING SAFETY BIOMARKERS IN NONCLINICAL STUDIES

EXHIBIT 85 GLOBAL OTHER BIOMARKERS MARKET 2021–2027 ($ BILLION)

EXHIBIT 86 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 87 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 88 GLOBAL BIOMARKERS MARKET BY GEOGRAPHY

EXHIBIT 89 GLOBAL BIOMARKERS MARKET BY GEOGRAPHY – INCREMENTAL GROWTH ($ BILLION)

EXHIBIT 90 GLOBAL BIOMARKERS MARKET BY GEOGRAPHY – ABSOLUTE GROWTH (%)

EXHIBIT 91 NORTH AMERICA BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 92 NORTH AMERICA BIOMARKERS MARKET – KEY COUNTRIES 2021 ($ BILLION)

EXHIBIT 93 BIOMARKERS MARKET IN NORTH AMERICA 2021–2027 ($ BILLION)

EXHIBIT 94 INCREMENTAL GROWTH BY TYPE 2021 & 2027

EXHIBIT 95 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027

EXHIBIT 96 INCREMENTAL GROWTH BY TYPE 2021 & 2027

EXHIBIT 97 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027

EXHIBIT 98 PERSONALIZED MEDICINES WITH SPECIFIC BIOMARKERS – TOP 20% OF FDA APPROVALS 2005-2019

EXHIBIT 99 APPROVED THERAPEUTIC MOLECULAR ENTITIES IN PERSONALIZED MEDICINE IN 2019

EXHIBIT 100 BIOMARKERS MARKET IN THE US 2021–2027 ($ BILLION)

EXHIBIT 101 CIHR PROJECTED LEVERAGE BY PARTNER TYPE FOR PERSONALIZED MEDICINE BUSINESS

EXHIBIT 102 BIOMARKERS MARKET IN CANADA 2021–2027 ($ BILLION)

EXHIBIT 103 EUROPE BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 104 EUROPE BIOMARKERS MARKET – KEY COUNTRIES 2021 ($ BILLION)

EXHIBIT 105 BIOMARKERS MARKET IN EUROPE 2021–2027 ($ BILLION)

EXHIBIT 106 INCREMENTAL GROWTH BY TYPE 2021 & 2027

EXHIBIT 107 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027

EXHIBIT 108 INCREMENTAL GROWTH BY INDICATION 2021 & 2027

EXHIBIT 109 INCREMENTAL GROWTH IN EUROPE 2021 & 2027

EXHIBIT 110 BIOMARKERS MARKET IN GERMANY 2021–2027 ($ BILLION)

EXHIBIT 111 BIOMARKERS MARKET IN FRANCE 2021–2027 ($ BILLION)

EXHIBIT 112 BIOMARKERS MARKET IN THE UK 2021–2027 ($ BILLION)

EXHIBIT 113 BIOMARKERS MARKET IN ITALY 2021–2027 ($ BILLION)

EXHIBIT 114 BIOMARKERS MARKET IN SPAIN 2021–2027 ($ BILLION)

EXHIBIT 115 APAC BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 116 APAC BIOMARKERS MARKET – KEY COUNTRIES 2021 ($ BILLION)

EXHIBIT 117 BIOMARKERS MARKET IN APAC 2021–2027 ($ BILLION)

EXHIBIT 118 INCREMENTAL GROWTH BY TYPE 2021 & 2027

EXHIBIT 119 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027

EXHIBIT 120 INCREMENTAL GROWTH BY INDICATION 2021 & 2027

EXHIBIT 121 INCREMENTAL GROWTH IN APAC 2021 & 2027

EXHIBIT 122 BIOMARKERS MARKET IN JAPAN 2021–2027 ($ BILLION)

EXHIBIT 123 BIOMARKERS MARKET IN CHINA 2021–2027 ($ BILLION)

EXHIBIT 124 BIOMARKERS MARKET IN INDIA 2021–2027 ($ BILLION)

EXHIBIT 125 BIOMARKERS MARKET IN SOUTH KOREA 2021–2027 ($ BILLION)

EXHIBIT 126 BIOMARKERS MARKET IN AUSTRALIA 2021–2027 ($ BILLION)

EXHIBIT 127 LATIN AMERICA BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 128 LATIN AMERICA BIOMARKERS MARKET – KEY COUNTRIES 2021 ($ BILLION)

EXHIBIT 129 BIOMARKERS MARKET IN LATIN AMERICA 2021–2027 ($ BILLION)

EXHIBIT 130 INCREMENTAL GROWTH BY TYPE 2021 & 2027

EXHIBIT 131 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027

EXHIBIT 132 INCREMENTAL GROWTH BY INDICATION 2021 & 2027

EXHIBIT 133 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027

EXHIBIT 134 BIOMARKERS MARKET IN BRAZIL 2021–2027 ($ BILLION)

EXHIBIT 135 BIOMARKERS MARKET IN MEXICO 2021–2027 ($ BILLION)

EXHIBIT 136 BIOMARKERS MARKET IN ARGENTINA 2021–2027 ($ BILLION)

EXHIBIT 137 MIDDLE EAST & AFRICA BIOMARKERS MARKET – INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 138 MIDDLE EAST & AFRICA BIOMARKERS MARKET – KEY COUNTRIES 2021 ($ BILLION)

EXHIBIT 139 BIOMARKERS MARKET IN THE MIDDLE EAST & AFRICA 2021–2027 ($ BILLION)

EXHIBIT 140 INCREMENTAL GROWTH BY TYPE 2021 & 2027

EXHIBIT 141 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027

EXHIBIT 142 INCREMENTAL GROWTH BY INDICATION 2021 & 2027

EXHIBIT 143 INCREMENTAL GROWTH IN THE MIDDLE EAST & AFRICA 2021 & 2027

EXHIBIT 144 BIOMARKERS MARKET IN TURKEY 2021–2027 ($ BILLION)

EXHIBIT 145 BIOMARKERS MARKET IN SOUTH AFRICA 2021–2027 ($ BILLION)

EXHIBIT 146 BIOMARKERS MARKET IN SAUDI ARABIA 2021–2027 ($ BILLION)

EXHIBIT 147 ABBOTT: TOTAL REVENUE 2018-2020 ($ BILLION)

EXHIBIT 148 ABBOTT: R&D EXPENDITURE 2018-2020 ($ BILLION)

EXHIBIT 149 BIOMÉRIEUX: R&D EXPENDITURE 2018-2020 ($ BILLION)

EXHIBIT 150 BIOMÉRIEUX: TOTAL REVENUE 2018-2020 ($ BILLION)

EXHIBIT 151 BIOHIT OYJ: TOTAL REVENUE 2018-2020 ($ BILLION)

EXHIBIT 152 BIOHIT OYJ: MARKET SHARE BY GEOGRAPHY (2020)

EXHIBIT 153 CENTOGENE: TOTAL REVENUE 2018-2020 ($ BILLION)

EXHIBIT 154 CENTOGENE: R&D EXPENDITURE 2018-2020 ($ BILLION)

EXHIBIT 155 CENTOGENE: REVENUE BY PHARMACEUTICAL SEGMENT 2018-2020 ($ BILLION)

EXHIBIT 156 CENTOGENE: MARKET SHARE BY GEOGRAPHY (2020)

EXHIBIT 157 F. HOFFMANN-LA ROCHE: TOTAL REVENUE 2018-2020 ($ BILLION)

EXHIBIT 158 GE HEALTHCARE: TOTAL REVENUE 2018-2020 ($ BILLION)

EXHIBIT 159 GE HEALTHCARE: MARKET SHARE OF HEALTHCARE SEGMENT BY GEOGRAPHY (2020)

LIST OF TABLES

TABLE 1 KEY CAVEATS

TABLE 2 CURRENCY CONVERSION 2015−2021

TABLE 3 TYPES OF BIOMARKERS

TABLE 4 PIPELINE BIOMARKERS

TABLE 5 PORTABLE BIOSENSORS FOR BIOMARKER DETECTION FROM SALIVA

TABLE 6 SUMMARY OF PORTABLE BIOSENSORS FOR BIOMARKER DETECTION FROM SWEAT

TABLE 7 SUMMARY OF PORTABLE BIOSENSORS FOR BIOMARKER DETECTION FROM BLOOD

TABLE 8 SUMMARY OF PORTABLE BIOSENSORS FOR BIOMARKER DETECTION FROM TEARS/BREATH

TABLE 9 TIME FRAME FOR BIOMARKER DEVELOPMENT

TABLE 10 AVERAGE COST RANGES FOR PREDICTIVE BIOMARKERS AND CLINICAL TRIAL ENDPOINTS BY PHASE OF BIOMARKER DEVELOPMENT

TABLE 11 ORIGINS OF 165 FALSE POSITIVE BIOMARKERS OBTAINED

TABLE 12 PROBLEMS AT EACH STAGE OF THE BIOMARKER RESEARCH PIPELINE

TABLE 13 STEPS IN FDA BIOMARKER QUALIFICATION PROGRAM PROCEDURE

TABLE 14 BIOSENSORS FOR IMPROVED DETECTION OF DIAGNOSTIC BIOMARKERS FROM VARIOUS SOURCES

TABLE 15 METHYLATION: PROGNOSTIC AND PREDICTIVE BIOMARKERS WITH DIAGNOSTIC ABILITY

TABLE 16 HISTONE MODIFICATIONS: PROGNOSTIC & PREDICTIVE BIOMARKERS WITH DIAGNOSTIC UTILITY

TABLE 17 MICRORNA: PROGNOSTIC AND PREDICTIVE BIOMARKERS WITH DIAGNOSTIC UTILITY

TABLE 18 EXAMPLES OF SUCCESSFULLY DEVELOPED PREDICTIVE BIOMARKERS IN MODERN ONCOLOGY

TABLE 19 ABBOTT: MAJOR PRODUCT OFFERINGS

TABLE 20 BIOMÉRIEUX: MAJOR PRODUCT OFFERINGS

TABLE 21 BIOHIT OYJ: MAJOR PRODUCT OFFERINGS

TABLE 22 CENTOGENE: MAJOR PRODUCT OFFERINGS

TABLE 23 CREATIVE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 24 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS

TABLE 25 FUJIREBIO: MAJOR PRODUCT OFFERINGS

TABLE 26 GE HEALTHCARE: MAJOR PRODUCT OFFERINGS

TABLE 27 TAMIRNA: MAJOR PRODUCT OFFERINGS

TABLE 28 GLOBAL BIOMARKERS MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)

TABLE 29 GLOBAL BIOMARKERS MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 30 GLOBAL BIOMARKERS MARKET BY INDICATION 2021−2027 ($ BILLION)

TABLE 31 GLOBAL BIOMARKERS MARKET BY INDICATION 2021−2027 (%)

TABLE 32 GLOBAL BIOMARKERS MARKET BY APPLICATION 2021−2027 ($ BILLION)

TABLE 33 GLOBAL BIOMARKERS MARKET BY APPLICATION 2021−2027 (%)

TABLE 34 GLOBAL BIOMARKERS MARKET BY TYPE 2021−2027 ($ BILLION)

TABLE 35 GLOBAL BIOMARKERS MARKET BY TYPE 2021−2027 (%)

TABLE 36 NORTH AMERICA BIOMARKERS MARKET BY INDICATION 2021−2027 ($ BILLION)

TABLE 37 NORTH AMERICA BIOMARKERS MARKET BY INDICATION 2021−2027 (%)

TABLE 38 NORTH AMERICA BIOMARKERS MARKET BY APPLICATION 2021−2027 ($ BILLION)

TABLE 39 NORTH AMERICA BIOMARKERS MARKET BY APPLICATION 2021−2027 (%)

TABLE 40 NORTH AMERICA BIOMARKERS MARKET BY TYPE 2021−2027 ($ BILLION)

TABLE 41 NORTH AMERICA BIOMARKERS MARKET BY TYPE 2021−2027 (%)

TABLE 42 EUROPE BIOMARKERS MARKET BY INDICATION 2021−2027 ($ BILLION)

TABLE 43 EUROPE BIOMARKERS MARKET BY INDICATION 2021−2027 (%)

TABLE 44 EUROPE BIOMARKERS MARKET BY APPLICATION 2021−2027 ($ BILLION)

TABLE 45 EUROPE BIOMARKERS MARKET BY APPLICATION 2021−2027 (%)

TABLE 46 EUROPE BIOMARKERS MARKET BY TYPE 2021−2027 ($ BILLION)

TABLE 47 EUROPE BIOMARKERS MARKET BY TYPE 2021−2027 (%)

TABLE 48 APAC BIOMARKERS MARKET BY INDICATION 2021−2027 ($ BILLION)

TABLE 49 APAC BIOMARKERS MARKET BY INDICATION 2021−2027 (%)

TABLE 50 APAC BIOMARKERS MARKET BY APPLICATION 2021−2027 ($ BILLION)

TABLE 51 APAC BIOMARKERS MARKET BY APPLICATION 2021−2027 (%)

TABLE 52 APAC BIOMARKERS MARKET BY TYPE 2021−2027 ($ BILLION)

TABLE 53 APAC BIOMARKERS MARKET BY TYPE 2021−2027 (%)

TABLE 54 LATIN AMERICA BIOMARKERS MARKET BY INDICATION 2021−2027 ($ BILLION)

TABLE 55 LATIN AMERICA BIOMARKERS MARKET BY INDICATION 2021−2027 (%)

TABLE 56 LATIN AMERICA BIOMARKERS MARKET BY APPLICATION 2021−2027 ($ BILLION)

TABLE 57 LATIN AMERICA BIOMARKERS MARKET BY APPLICATION 2021−2027 (%)

TABLE 58 LATIN AMERICA BIOMARKERS MARKET BY TYPE 2021−2027 ($ BILLION)

TABLE 59 LATIN AMERICA BIOMARKERS MARKET BY TYPE 2021−2027 (%)

TABLE 60 MIDDLE EAST & AFRICA BIOMARKERS MARKET BY INDICATION 2021−2027 ($ BILLION)

TABLE 61 MIDDLE EAST & AFRICA BIOMARKERS MARKET BY INDICATION 2021−2027 (%)

TABLE 62 MIDDLE EAST & AFRICA BIOMARKERS MARKET BY APPLICATION 2021−2027 ($ BILLION)

TABLE 63 MIDDLE EAST & AFRICA BIOMARKERS MARKET BY APPLICATION 2021−2027 (%)

TABLE 64 MIDDLE EAST & AFRICA BIOMARKERS MARKET BY TYPE 2021−2027 ($ BILLION)

TABLE 65 MIDDLE EAST & AFRICA BIOMARKERS MARKET BY TYPE 2021−2027 (%)

Select a license type that suits your business needs

single-user Single User Licence
$3750.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4250.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5250.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date